NovoCure (NASDAQ:NVCR) insider Yoram Palti sold 60,000 shares of the stock in a transaction on Tuesday, April 3rd. The shares were sold at an average price of $20.32, for a total transaction of $1,219,200.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Yoram Palti also recently made the following trade(s):
- On Thursday, March 29th, Yoram Palti sold 30,000 shares of NovoCure stock. The shares were sold at an average price of $21.67, for a total transaction of $650,100.00.
Shares of NVCR opened at $19.85 on Friday. The firm has a market cap of $1,829.11, a price-to-earnings ratio of -28.36 and a beta of 3.16. The company has a debt-to-equity ratio of 0.86, a current ratio of 4.88 and a quick ratio of 4.44. NovoCure has a twelve month low of $10.30 and a twelve month high of $24.15.
Several research firms recently commented on NVCR. ValuEngine raised shares of NovoCure from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. BidaskClub raised shares of NovoCure from a “sell” rating to a “hold” rating in a report on Friday, March 9th. Zacks Investment Research lowered shares of NovoCure from a “buy” rating to a “hold” rating in a report on Saturday, January 13th. Mizuho reaffirmed a “buy” rating and set a $28.00 target price (up previously from $25.00) on shares of NovoCure in a report on Friday, February 23rd. Finally, Deutsche Bank reduced their target price on shares of NovoCure from $22.00 to $19.00 and set a “hold” rating on the stock in a report on Friday, February 23rd. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $19.71.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Farallon Capital Management LLC purchased a new stake in NovoCure during the 4th quarter valued at $23,533,000. Frontier Capital Management Co. LLC boosted its position in NovoCure by 29.8% during the 4th quarter. Frontier Capital Management Co. LLC now owns 1,081,898 shares of the medical equipment provider’s stock valued at $21,854,000 after buying an additional 248,322 shares during the period. Tamarack Advisers LP purchased a new stake in NovoCure during the 4th quarter valued at $21,311,000. Peregrine Capital Management LLC boosted its position in NovoCure by 38.0% during the 4th quarter. Peregrine Capital Management LLC now owns 865,671 shares of the medical equipment provider’s stock valued at $17,487,000 after buying an additional 238,195 shares during the period. Finally, Allianz Asset Management GmbH purchased a new stake in NovoCure during the 4th quarter valued at $10,760,000. 42.83% of the stock is owned by institutional investors and hedge funds.
NovoCure Company Profile
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.
Receive News & Ratings for NovoCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure and related companies with MarketBeat.com's FREE daily email newsletter.